Therefore, blockade of PGK1 or ALDOA should be considered as a potential immunotherapeutic strategy to boost AhR activation and ultimately control Th17 cell inflammatory potential while favoring the acquisition of suppressive features by these cells in Crohn’s disease. The gene discussed is PGK1; the disease is Crohn disease.